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 Hepatocellular adenoma <5 cm bears minimal risk for a
pregnant woman and none for the child.
 In a quarter of cases the hepatocellular adenoma increased in
size during pregnancy.
 Neither tumour rupture nor haemorrhage was observed
during the study period.
 Close monitoring is recommended in pregnant women with
hepatocellular adenoma.Marcia Patricia Gaspersz, Anne Julia
Klompenhouwer, Mirelle Elmira Elizabeth
Broker, ..., Harry de Koning, Robert Auke de





The presence of hepatocellular adenoma
in pregnant women requires special con-
sideration, as it carries the risk of growth
and haemorrhage. In this study we fol-
lowed 48 patients with hepatocellular
adenoma <5 cm during 51 pregnancies
and found that a hepatocellular adenoma
during pregnancy confers minimal risk to
the pregnant woman and none to her
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nancy confers minimal risk to the pregnant woman and none
to her child.
weight reduction.3,4
Several HCA subtypes can be distinguished radiologically on
contrast-enhanced MRI with hepatobiliary contrast agents (LCE-
MRI)5,6) or on the basis of immunohistochemical staining or
molecular characterization. They include hepatocyte nuclear
factor 1a inactivated (H-HCA), inflammatory (I-HCA), b-
catenin-activated (b-HCA), b-catenin-activated inflammatory
(b-IHCA), and sonic hedgehog (sh-HCA) adenomas.7,8 If specific
mutations are not found, the HCA is labelled unclassified (U-
HCA). Resection of an HCA >5 cm is usually advocated if it does
not regress to <5 cm within 12 months, because the risk of com-
plications is thought to be higher in HCA >5 cm.9–12
In pregnant women, HCA requires special attention because
of the risk of hormone-induced growth and rupture, which
may threaten the life of both mother and child. Cobey and Salem
reported that the mortality risk of ruptured HCA >6.5 cm during
pregnancy was 44% for the mothers and 38% for the foetuses
[13]. However, almost all cases included in this review dated
from the 1970s and 1980s. In 2011, our research group pro-
posed close monitoring of pregnant women with small HCA
instead of intervention, and suggested that women with small
HCA should not be discouraged to fall pregnant. This suggestion
was based on a study in which we monitored 12 women with
documented HCA (5 with HCA >5 cm and 7 with HCA <5 cm)
during a total of 17 pregnancies.14,15 All pregnancies in thisCenter Rotterdam, The Netherlands; Department of Public Health,
5Department of Gastroenterology and Hepatology, Erasmus
Background & Aims: The presence of hepatocellular adenoma
(HCA) in pregnant women requires special consideration, as it
has been reported to carry the risk of growth and clinically sig-
nificant haemorrhage. In this prospective study we assessed
aspects of growth of HCA <5 cm during pregnancy.
Methods: This was a multicentre prospective cohort study in
pregnant women with suspected HCA <5 cm on imaging. Defini-
tive HCA diagnosis was established by MRI with hepatobiliary
contrast agents (LCE-MRI), preferably before pregnancy. If at
study inclusion a definitive diagnosis was lacking, LCE-MRI
was performed after giving birth. Growth of the adenoma
(defined as an increase of >20%) was closely monitored with
ultrasound examinations throughout pregnancy.
Results: Of the 66 women included, 18 were excluded from
analysis because postpartum LCE-MRI did not confirm the diag-
nosis of HCA and showed the lesion to be focal nodular hyper-
plasia. The remaining 48 women, with an HCA confirmed by
LCE-MRI, were followed during 51 pregnancies. Median age
was 30 years (IQR 27–33) and median body mass index
31.9 kg/m2 (IQR 26.3–36.6). Growth of HCA was seen in 13 of
the pregnancies (25.5%); the median increase was 14 mm (IQR
8–19). One woman whose HCA grew to >70 mm successfully
underwent transarterial embolization at week 26 of pregnancy
to prevent further growth. The other 50 pregnancies proceeded
without complications.
Conclusion: This study suggests that an HCA <5 cm confers
minimal risk to a pregnant woman and none to her child. HCA
increased in size during a quarter of pregnancies, so we recom-
mend close monitoring with ultrasound examinations, enabling
intervention if needed. In light of the large proportion of misdi-
agnosed HCA, LCE-MRI should be performed to prevent unnec-
essary anxiety in women with a benign liver lesion.
Keywords: Adenoma Liver Cell; Pregnancy; Follow-Up Studies; MRI.
Received 5 July 2019; received in revised form 28 August 2019; accepted 10 September
2019
⇑ Corresponding author. Address: Erasmus MC, University Medical Center Rotter-
dam, Department of Surgery, Dr. Molewaterplein 40, 3015 GD Rotterdam, The
Netherlands. Tel.: +31 10 7031810, fax: +31 10 2250647.
E-mail address: j.ijzermans@erasmusmc.nl (J.N.M. Ijzermans).
y Shared first authorship.Journal of Hepatology 2
Please cite this article in press as: Gaspersz MP et al. Growth of hepatocellular adenom
jhep.2019.09.011enoma during pregnancy:
ive study
houwer1,⇑,y, Mirelle Elmira Elizabeth Broker1,
anna Maria van Aalten1, Eric Steegers3,
uke de Man5, Jan Nicolaas Maria Ijzermans1
terdam, The Netherlands; 2Department of Radiology, Erasmus MC,
t of Obstetrics and Gynaecology, Erasmus MC, University Medical
asmus MC, University Medical Center Rotterdam, The Netherlands;
C, University Medical Center Rotterdam, The Netherlands
Lay summary: The presence of hepatocellular adenoma in preg-
nant women requires special consideration, as it carries the risk
of growth and haemorrhage. In this study we followed 48
patients with hepatocellular adenoma <5 cm during 51 preg-
nancies and found that a hepatocellular adenoma during preg- 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. All rights reserved.
Introduction
Hepatocellular adenoma (HCA) occurs particularly among
reproductive women and is associated with the use of
oestrogen-containing oral contraceptives, androgen intake, obe-
sity, and metabolic disorders.1,2 The tumour may regress upon
cessation of oestrogen-containing oral contraceptives and019 vol. xxx j xxx–xxx
a during pregnancy: A prospective study. J Hepatol (2019), https://doi.org/10.1016/j.
Research Article Hepatic and Biliary Cancerstudy had an uneventful course without adverse maternal or
foetal outcomes.
Data on the behaviour of HCA during pregnancy and the fac-
tors that influence safety are still very limited. In this prospec-
tive study we assessed the effect of pregnancy on the
biological behaviour of HCA, including the incidence of growth,
the occurrence of complications and HCA-related interventions
during pregnancy. To select a group of women with an a priori
low risk of complications, we set the maximum HCA size at
5 cm, as the relevant European guidelines state that HCA
<5 cm carry low risk of haemorrhage.11
Patients and methods
Study design and population
This was a multicentre prospective cohort study performed in
the Netherlands, the coordinating centre being a tertiary referral
centre for focal liver lesions. The study protocol was reviewed
and approved by the institutional review board, has been pub-
lished before and was registered in the Dutch trial register
(NTR3034).16
We included pregnant women over 18 years of age who had
been diagnosed with single or multiple HCA – the largest not
exceeding 5 cm at the moment of inclusion. Pregnancy had to
be confirmed by an obstetrician or midwife with ultrasound
(US) examination. Patients were included regardless of parity.
The definite HCA diagnosis was based on LCE-MRI or biopsy,
preferably performed before pregnancy because contrast agents
might be toxic during pregnancy. When the lesion was found
incidentally during pregnancy, LCE-MRI was performed post-
partum. Exclusion criteria for the per protocol analysis were
lack of LCE-MRI or biopsy, no confirmation of the diagnosis
HCA on LCE-MRI, and termination of the pregnancy. Inclusion
was open from November 2011 until January 2019.
Study procedures
Eligible women were invited to participate by their treating
physicians at the outpatient clinic. Those who were interested
were sent a letter explaining the study aims and were contacted
by telephone to provide additional information and answer
questions. Those who provided written informed consent com-
pleted a questionnaire registering: date of birth, length and
weight, use of hormonal supplements before pregnancy (includ-
ing possible fertility treatment), comorbidities, parity and esti-
mated date of delivery.
The participants were scheduled for repetitive US examina-
tion at 14 (+/ 3), 20, 26, 32, 38 weeks of gestation and 6–
12 weeks postpartum at their preferred hospital. The US exam-
inations were performed by either a radiologist or a hepatolo-
gist with experience in hepatic US, who assessed HCA number,
location, size, possible growth or regression, as well as US char-
acteristics. Lesion growth was defined as an increase of >20% in
transversal diameter and lesion regression as a decrease of >30%
as per the response evaluation in solid tumours (RECIST) crite-
ria.17 In case of suspected growth or atypical US characteristics
during pregnancy, a conventional MRI (without contrast agents)
was performed; the coordinating centre was consulted; and the
hepatobiliary multidisciplinary tumour board considered the
optimum treatment.
The US reports of participants in the various centres were
collected at the coordinating centre. Apart from HCA size at all
time points, data on complications during pregnancy, vaginal
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time of diagnosis and prior to pregnancy were recorded. In addi-
tion, the HCA subtype was documented on the basis of immuno-
histochemistry or pathomolecular characterization when biopsy
material was available, or on LCE-MRI features.5,6,18 If haemor-
rhage had occurred before pregnancy (causing a less reliable
subtype determination based on LCE-MRI) or the subtype was
not determined otherwise, the subtype remained undetermined
(‘missing’). The biological behaviour of HCA prior to pregnancy
was assessed, that is: regression, growth or stable prior, also
according to the RECIST criteria. The percentage of regression
was calculated as follows: (diameter HCA at diagnosis – diame-
ter HCA at last follow-up prior to pregnancy)/diameter HCA at
diagnosis.
Statistical analysis
Continuous variables are summarized as mean ± SD or as med-
ian and IQR. Categorical variables are presented as frequency (n)
and percentages. Comparative analysis was performed with the
Mann-Whitney U test for continuous variables and the v2 test
for categorical variables. All statistical analysis was performed
with SPSS software version 21.0 (IBM, Armonk, New York, USA).
Result
Inclusion and baseline characteristics
A total of 74 pregnant women diagnosed as having an HCA
<5 cm at the moment of inclusion were scheduled for close
monitoring with US during pregnancy. Four refrained from
follow-up, however, and 4 had a miscarriage, leaving 66 who
completed follow-up. Eighteen women (18/66; 27%) were
excluded from the analysis because LCE-MRI performed after
delivery showed the lesion to be focal nodular hyperplasia
Table 1. Baseline characteristics.
N (%) or median (IQR)
Age at inclusion (yr) (n = 51) 30 (27–33)
BMI (kg/m2) (n = 51) 31.9 (26.3–36.6)
Diameter HCA at diagnosis (mm) (n = 48) 33 (20–59)
Diabetes (n = 48)
Diabetes mellitus 3 (6.3)
Gestational diabetes 3 (6.3)
No 42 (88.8)





Hormone usage before pregnancy (n = 48)
Oral contraceptives 43 (89.6)
None 4 (8.3)
Other 1 (2.1)
Prior pregnancy (n = 51)
Yes 12 (23.5)
No 39 (76.5)
Fertility treatment (n = 51)
Yes 3 (5.9)
No 48 (94.1)
Delivery (n = 51)
Vaginal 45 (88.2)
Caesarean 6 (11.8)
Age, BMI and prior pregnancy are given per pregnancy (n = 51); the occurrences of
diabetes and hormone usage before pregnancy are given per patient (n = 48). BMI,
body mass index; HCA, hepatocellular adenoma; H-HCA, hepatocyte nuclear factor
1a inactivated HCA; I-HCA, inflammatory HCA; U-HCA, unclassified HCA.
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(FNH) instead of HCA. Ultimately, 51 datasets were analysed as
1 woman participated twice and 1 woman participated 3 times.
Baseline characteristics are depicted in Table 1.
In 40 pregnancies (40/51; 78%) the diagnosis HCA was con-
firmed with LCE-MRI prior to pregnancy. Three patients under-
went diagnostic biopsy confirming HCA diagnosis. The median
HCA diameter at diagnosis was 33 mm (IQR 20–59); at the last
imaging prior to pregnancy it was 23 mm (IQR 19–39). In 26
cases, regression had occurred after cessation of oral contracep-
tives prior to pregnancy; in 14 cases the HCA size had remained
stable. The other 11 HCAs were found incidentally during
pregnancy.
Follow-up during pregnancy
All 5 scheduled US examinations were performed in 18% of the
51 pregnancies; 4 examinations were performed in 54%; 3
examinations were performed in 22%; and 2 examinations were
performed in 6%. Reasons for missing examinations were inclu-
sion after 14 weeks of pregnancy, delivery prior to 38 weeks and
patient non-compliance. Postpartum US was performed in 70%
and showed either stable or regressing lesions.
In 27 of the 51 pregnancies (53%), the lesions remained
stable; in 11 (22%) they had regressed, and in 13 (25%) they
had grown. In all 13 cases, growth had occurred between 14
and 32 weeks of gestation; the median growth was 14 mm
(IQR 8–19) (Fig. 1). During pregnancy, HCA imaging indicating
bleeding was not found and lesion characteristics did not differ
between the subgroup of women with stable or regressing HCA
and the subgroup of women with growing lesions (p = 0.249,
Table 2). Additionally, there were no statistically significant dif-
ferences between these subgroups for age at inclusion, body
mass index (BMI) at inclusion, HCA diameter at diagnosis,
HCA subtype and the percentage of HCA regression before preg-
nancy (Table 2). One woman underwent a transarterial
embolization of the HCA during pregnancy because it had
grown from 49 mm at week 14 to a maximum of 76 mm at
week 20 (Fig. 2). She had been diagnosed with HCA 2 years prior
to pregnancy; at baseline it measured 93 mm and it regressed to
49 mm within 1 year after cessation of oral contraceptives
(Fig. 3). After the embolization, the lesion regressed to 65 mm
at week 26 and 51 mm at week 32. Labour was induced at
38 weeks, proceeded without complications, and resulted in
the birth of a healthy child. The other 50 pregnancies proceeded
without complications. Six patients had a caesarean delivery, all
because of reasons unrelated to HCA. The remaing deliveries
were vaginal with an uneventful course.
Three patients underwent fertility treatment in order to
become pregnant, of whom 2 underwent in vitro fertilisation
and 1 ovulation induction. Although no US examinations were
performed during the fertility therapy and therefore possible
growth of HCA was not monitored, clinically, the fertility treat-
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Fig. 1. Growing HCA during pregnancy. This figure shows the 13 growing
HCA during pregnancy at each time point: 14 (+/3), 20, 26, 32, 38 weeks of
gestation and 6–12 weeks postpartum). HCA, hepatocellular adenoma.
Table 2. Comparison of growing vs. stable/regressing lesions during pregnStable or reg
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Comparative analysis was performed with Mann-Whitney U test for continuous vari
pregnancy was calculated as followed: (diameter HCA at diagnosis – diameter HCA at
of HCA prior to pregnancy was assessed and it was documented whether the le
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the HCA showed growth in 1 patient and remained stable in the
other 2.
Two women were enrolled in the study more than once,
respectively 2 and 3 times. Both underwent LCE-MRI after each
pregnancy. The former had a lesion of 20 mm that remained
stable during the first pregnancy, and then regressed in the
2 years until the second pregnancy to a point where it was
not visible anymore. During the second pregnancy it grew to a
maximum of 13 mm. The latter had a lesion that remained
cy.
ression (n = 38) Growth (n = 13) p value
29 (27–32.3) 32 (29–34) 0.155
32.3 (26.1–37.6) 29.0 (27.1–35.9) 0.603
35.0 (20.0–64.0) 30.0 (20.0–60.0) 0.952
0.540
2 (5.3) 0 (0)
12 (31.6) 4 (30.8)
12 (31.6) 2 (15.4)
12 (31.6) 7 (53.8)
35.9 (13.9–59.5) 47.3 (0–73.0) 0.858
0.249
23 (60.5) 8 (61.5)
5 (13.2) 4 (30.8)
9 (23.7) 2 (15.4)
les and v2 test for categorical variables. The percentage of regression of HCA before
st follow-up prior to pregnancy)/diameter HCA at diagnosis. The biological behaviour
on regressed or was stable by the RECIST criteria. BMI, body mass index; HCA,
, inflammatory HCA; U-HCA, unclassified HCA.19 vol. xxx j xxx–xxx 3
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Research Article Hepatic and Biliary Cancerstable at 43 mm during the first and stable at 25 mm during the
second pregnancy, while it regressed during the third
pregnancy.
Five women had been diagnosed with haemorrhagic HCA
prior to pregnancy; all were hemodynamically stable and inter-
vention was judged unnecessary. The HCA grew during preg-
nancy in 2 women and remained stable in the other 3. Neither
of the lesions showed signs of haemorrhage during pregnancy.
None of the 18 women who were diagnosed with FNH post-
partum had undergone LCE-MRI prior to pregnancy in the hos-
pital where they were diagnosed. Suspicion of HCA had been
raised during conventional MRI (without hepatobiliary contrast
agent) in 12, US in 4, CT in 1 and contrast-enhanced US in 1.
Discussion
In this study of 51 pregnancies in 48 patients with HCA <5 cm,
we investigated the incidence of growth, occurrence of compli-
cations and HCA-related interventions during pregnancy. HCA
growth was defined as an increase of more than 20%, as per
the RECIST criteria, and this was seen in one-quarter of cases.
The median growth was 14 mm. Neither tumour rupture nor
haemorrhage was observed during the study period, and factors
predictive of growth could not be identified.
To the best of our knowledge, this is the first prospective
study investigating the biological behaviour of small HCA dur-
ing pregnancy. Until recently, the general consensus had been
that women with HCA should be discouraged to become preg-
nant without prior treatment – in view of the risk of clinically
A B
Fig. 2. Ultrasound of growing HCA. Patient who was diagnosed with a single H
the lesion regressed to 49 mm (B: last ultrasound prior to pregnancy). Dur
ultrasound showing growth during pregnancy). A transarterial embolization w
A B
Fig. 3. MRI of growing HCA. T2 weighted MRI images of a patient with a l
(93 mm) in the right hemiliver. (B) MRI performed during pregnancy due to su
on in the pregnancy, transarterial embolization was performed. (C) MRI p
embolization. HCA, hepatocellular adenoma.4 Journal of Hepatology 20
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A of 93 mm (A: ultrasound at diagnosis). After cessation of oral contraceptives
g pregnancy the lesion showed growth again to a maximum of 76 mm (C:
s performed. HCA, hepatocellular adenoma.ger single HCA. (A) Diagnostic contrast-enhanced MRI showing a large HCA
ected growth, showing a 65 mm lesion. As the lesion grew significantly early
tpartum, showing a 52 mm lesion with central necrosis after transarterialin a paper studying mainly cases from the 1970s and 1980s
it was reported that during pregnancy the mortality risk of
ruptured HCA may be as high as 44% for the mother and
38% for the foetus.13 It should be noted that this was at a
time in which the entity of HCA was less well-known and
embolization for acute haemorrhage was not yet available inOnly in 1 case, in which rapid growth of the lesion during
pregnancy was seen, was an intervention performed to reduce
the risk of haemorrhage. This patient had previously been diag-
nosed with a large HCA that had regressed to <5 cm within
1 year after cessation of oral contraceptives. The intervention
consisted of transarterial embolization; labour was uncompli-
cated and resulted in the birth of a healthy child. As other com-
plications did not occur in this cohort, we suggest that women
with HCA <5 cm who wish to conceive should not be discour-
aged or advised to refrain from this. Still, in view of the fact that
growth occurred in one-quarter of cases, shared decision mak-
ing with the patient and close monitoring during pregnancy is
indicated. We surmised that HCAs that regress after cessation
of oral contraceptives are more sensitive to hormones – and
therefore are more prone to grow during pregnancy. However,
we could not confirm this with the present data, probably
because of the lack of statistical power resulting from the small
sample size. Likewise, we could not detect differences between
HCA subtypes, although previous studies have shown different
probabilities of HCA regression and risk of complication for var-
ious HCA subtypes.8,19 Surprisingly, almost one-quarter of HCAs19 vol. xxx j xxx–xxx
a during pregnancy: A prospective study. J Hepatol (2019), https://doi.org/10.1016/j.
JOURNAL 
OF HEPATOLOGYin this study regressed during pregnancy. The exact mechanism
and reason for this regression remains unclear.
In this study, only 3 patients underwent fertility treatment in
order to become pregnant. No US examinations were performed
during fertility treatment as these patients were only included
after conception, but fertility treatment was described as
uneventful. Indeed, it would be interesting to monitor the size
of HCA during fertility treatment and its hormonal stimulation
and to relate the outcome with changes during pregnancy.
Future studies should aim to investigate the effect of fertility
treatment on HCA.
Two women in this study were enrolled more than once: 1
woman during 2 pregnancies and 1 woman during 3 pregnan-
cies. HCA behaviour was not the same in the consecutive preg-
nancies. An additional 9 women already had had an uneventful
pregnancy before being diagnosed with HCA, and all had
uneventful pregnancies again during this study. By way of com-
parison, in a previous study almost half of the women with HCA
had already carried at least 1 pregnancy to term before
diagnosis.20
The median BMI at inclusion of patients enrolled in this
study is fairly high. An association between HCA and obesity
has been well established in the literature.4,21–23 Additionally,
the median BMI in this study is comparable to the median of
previous study populations.12,19 Another notable result in the
baseline characteristics is the high fraction of patients with U-
HCA, especially compared to previously published studies.7 Pre-
vious studies regarding the distribution of HCA subtypes have
particularly been performed in cohorts of patients with larger
adenomas. An analysis regarding HCA subtype related to the
size has yet to be performed, but subtype distribution might dif-
fer between large and small HCAs. Additionally, biopsy is less
often performed when the lesion is small.
In the present study, a large proportion of suspected HCAs
actually proved to be FNH. Such a misdiagnosis could have a
major impact on the life of the young woman, as FNH is not
associated with hormone-induced growth and the lesion need
not be closely monitored during pregnancy. Therefore, we
highly recommend performing LCE-MRI if HCA is suspected
and the woman wishes to conceive.
Regrettably, we had to deviate from the original study proto-
col of the PALM study as published in 2012.16 This included 2
control groups for the purpose of assessing quality of life
aspects: one of healthy pregnant women without HCA and
one of pregnant women with diabetes mellitus. Because we
could not find women without HCA willing to undergo regular
liver US during pregnancy, these 2 control groups were dis-
carded. Venipuncture, as described in the protocol, was dis-
carded as well, because the majority of participants were
unwilling to undergo venipuncture.
This study is subject to some limitations. First, only 18% of
participants underwent the US examination at every planned
follow-up moment. The incomplete data do not, however, affect
the primary study outcome. Second, the study cohort was too
small to identify with a high degree of certainty risk factors
for rupture, bleeding or growth. Nevertheless, considering the
rareness of this liver tumour, the sample size was relatively
large. Future studies should aim to identify risk factors for
pregnancy-related haemorrhage or growth of HCA. Lesion char-
acteristics such as HCA subtype or HCA response after cessation
of oral contraceptives might affect the risk of rupture or
bleeding.8
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cohort large enough to identify subgroups at risk of
pregnancy-related complications. Taking biopsies could help
to identify HCA subtypes and define women at risk who may
benefit from follow-up and those who do not require follow-
up due to the very low risk of complications. To gain more
insight into the accuracy of diagnostics, the biological behaviour
of HCA during pregnancies, and the risk of growth and haemor-
rhage of HCA during pregnancy, we initiated the EuroPALM reg-
istry, which will enable the field to create a large international
cohort.
In conclusion, this study indicates that in well-diagnosed
patients, an HCA smaller than 5 cm during pregnancy seems
to bear minimal risk for the mother and no risk for the foetus.
As it cannot be excluded that an HCA will grow during preg-
nancy, we recommend close monitoring with ultrasound
examinations.
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